Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I Study of DS-3032B in Combination with Quizartinib in Subjects with FLT3-ITD Mutant Acute Myeloid Leukemia That are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
Phase I/II Open-Label Study to Evaluate the Safety and Preliminary Efficacy of Mrx0518 in Combination with Pembrolizumab in Patients with Non-Small-Cell Lung Cancer, Renal Cell Carcinoma, Bladder Cancer, and Melanoma Who Have Progressed on PD-1 Inhibitors
A Phase II Study of Loxo-292 in Patients with Ret Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer LUNG-MAP Sub-Study
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion before Tumor-Infiltrating Lymphocyte Therapy with Lifileucel in Metastatic Melanoma
Study Type: Treatment
Phase: II
NCTID: NCT06151847
Principal Investigator:
Muhammad Umair Mushtaq
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician?s Choice in Subjects with Fibroblast Growth Factor Receptor FGFR-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma FIRST-308
Randomized Phase III Trial of Mfolfirnox +/- Nivolumab Vs. Folfox +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
A Phase Ib/II Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia AML
Study Type: Treatment
Phase: I/II
NCTID: NCT06634394
Principal Investigator:
Tara Lin
A Phase III Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features
Study Type: Treatment
Phase: III
NCTID: NCT05382338
Principal Investigator:
Keith August
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Study Type: Treatment
Phase: I
NCTID: NCT05476770
Principal Investigator:
Keith August